CKD-702 Plus Irinotecan in Gastric Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Gastric Cancer

Interventions

DRUG

CKD-702 in combination with irinotecan

CKD-702 and irinotecan will be intravenously administered every 2 weeks.

Trial Locations (1)

RECRUITING

National Cancer Center, Goyang-si

All Listed Sponsors

lead

National Cancer Center, Korea

OTHER_GOV